← Back to Clinical Trials
Recruiting NCT04005976

NCT04005976 Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04005976
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center, Houston
Condition Aortic Aneurysm
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2016-06-15
Primary Completion 2037-01-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2016-06-15 with a primary completion date of 2037-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers of H-TAD.

Eligibility Criteria

Inclusion Criteria: * Patients and their relatives with a confirmed pathogenic, likely pathogenic variant, or variant of unknown clinical significance in at least one of the H-TAD genes (i.e. TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, MYLK, PRKG1, MAT2A, MFAP5, LOX, COL3A1, FOXE3, and FBN1). * Patients of all ages, sex and race for which informed consent can be obtained. Exclusion Criteria: * Patients without a confirmed causative variant for H-TAD.

Contact & Investigator

Central Contact

Dianna M Milewicz, MD, PhD

✉ Dianna.M.Milewicz@uth.tmc.edu

📞 713-500-6725

Principal Investigator

Dianna Milewicz, MD, PhD

STUDY DIRECTOR

UTHealth

Frequently Asked Questions

Who can join the NCT04005976 clinical trial?

This trial is open to participants of all sexes, studying Aortic Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04005976 currently recruiting?

Yes, NCT04005976 is actively recruiting participants. Contact the research team at Dianna.M.Milewicz@uth.tmc.edu for enrollment information.

Where is the NCT04005976 trial being conducted?

This trial is being conducted at Newport Beach, United States, Newport Beach, United States, Sacramento, United States, Lexington, United States and 11 additional locations.

Who is sponsoring the NCT04005976 clinical trial?

NCT04005976 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Dianna Milewicz, MD, PhD at UTHealth. The trial plans to enroll 5,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology